Stocks-JAZZ-Jazz Pharmaceuticals

JAZZ Jazz Pharmaceuticals

133.82 -0.29 (-0.22%)
Market OpenDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Jazz Pharmaceuticals's revenues increased by 18.26% and amounted to 3.66B. Net income increased by 32.03% to -224.06M. Net assets decreased by 22.18% to 3.09B and EPS increased from -5.52 to -3.58.
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
Net Profit Margin
Operating Margin
Return On Investment